Glycoprotein IIb/IIIa Inhibition After Clopidogrel Loading for Primary Percutaneous Coronary Intervention

In a randomized trial, abciximab showed no benefit in clopidogrel-treated STEMI patients.

The glycoprotein IIb/IIIa inhibitor abciximab has demonstrated beneficial effects, both in patients with ST-segment-elevation MI undergoing primary percutaneous coronary intervention without clopidogrel pretreatment and in high-risk patients with acute coronary syndromes undergoing elective PCI with clopidogrel pretreatment. In this randomized, double-blind trial, 800 STEMI patients undergoing primary PCI <24 hours after symptom onset were treated with 600 mg of clopidogrel (median, 74 minutes before PCI) and then received abciximab or placebo before catheterization.

Infarct size (the primary study endpoint), assessed by SPECT imaging in 94% of patients 4 to 5 days after PCI, was 15.7% of the left ventricle in the abciximab group and 16.6% i…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI